Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma

Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survi...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2024-04, Vol.21 (6), p.2960-2969
Main Authors: Pun, Michael D., Gallazzi, Fabio, Ho, Khanh-Van, Watkinson, Lisa, Carmack, Terry L., Iweha, Ejike, Li, Longbo, Anderson, Carolyn J.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-a307t-336090a7bfdb3466f558fc7350991caba1fda8d9c9801ae7d2dfce0c8cffc2393
container_end_page 2969
container_issue 6
container_start_page 2960
container_title Molecular pharmaceutics
container_volume 21
creator Pun, Michael D.
Gallazzi, Fabio
Ho, Khanh-Van
Watkinson, Lisa
Carmack, Terry L.
Iweha, Ejike
Li, Longbo
Anderson, Carolyn J.
description Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads. An analog of [177Lu]­Lu-labeled-LLP2A was previously investigated as a therapeutic agent in melanoma tumor-bearing mice, resulting in only a modest improvement in tumor growth inhibition, likely due to rapid clearance of the agent from the tumor. To improve the pharmacokinetic profile, DOTAGA-PEG4-LLP2A with a 4-(p-iodophenyl)­butyric acid (pIBA) albumin binding moiety was synthesized. We demonstrate the feasibility of this albumin binding strategy by comparing in vitro cell binding assays and in vivo biodistribution performance of [177Lu]­Lu-DOTAGA-PEG4-LLP2A ([177Lu]­Lu-1) to the albumin binding [177Lu]­Lu-DOTAGA-pIBA-PEG4-LLP2A ([177Lu]­Lu-2). In vitro cell binding assay results for [177Lu]­Lu-1 and [177Lu]­Lu-2 showed K d values of 0.40 ± 0.07 and 1.75 ± 0.40 nM, with similar B max values of 200 ± 6 and 315 ± 15 fmol/mg, respectively. In vivo biodistribution data for both tracers exhibited specific uptake in the tumor, spleen, thymus, and bone due to endogenous expression of VLA-4. Compound [177Lu]­Lu-2 exhibited a much longer blood circulation time compared to [177Lu]­Lu-1. The tumor uptake for [177Lu]­Lu-1 was highest at 1 h (∼15%ID/g) and that for [177Lu]­Lu-2 was highest at 4 h (∼23%ID/g). Significant clearance of [177Lu]­Lu-1 from the tumor occurs at 24 h (
doi_str_mv 10.1021/acs.molpharmaceut.4c00095
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3048496124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3048496124</sourcerecordid><originalsourceid>FETCH-LOGICAL-a307t-336090a7bfdb3466f558fc7350991caba1fda8d9c9801ae7d2dfce0c8cffc2393</originalsourceid><addsrcrecordid>eNqNkM1OwzAQhC0EoqXwCijcuKSsYyexj6X8SkEgUc6R49jUVZwUO67E25OqpRI3TrsrzczufghdYZhiSPCNkH5qu2a9FM4KqUI_pRIAeHqExjilJGaEJ8eHntEROvN-BZDQNCGnaERYxgBSPkbvs6YK1rTxrWlr035GRehVb4KNcZ7HhahUo-qoKN6SWXSnnNmI3myUj4SPFkvlRNv53kgf6c5FL6oZZivO0YkWjVcX-zpBHw_3i_lTXLw-Ps9nRSwI5H1MSAYcRF7puiI0y3SaMi1zkgLnWIpKYF0LVnPJGWCh8jqptVQgmdRaJoSTCbre5a5d9xWU70trvFTNcIXqgi8JUEZ5hhM6SPlOKl3nvVO6XDtjhfsuMZRbpuXAtPzDtNwzHbyX-zWhsqo-OH8hDoJ0J9hmrLrg2uHrfwT_AOI8iw4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3048496124</pqid></control><display><type>article</type><title>Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Pun, Michael D. ; Gallazzi, Fabio ; Ho, Khanh-Van ; Watkinson, Lisa ; Carmack, Terry L. ; Iweha, Ejike ; Li, Longbo ; Anderson, Carolyn J.</creator><creatorcontrib>Pun, Michael D. ; Gallazzi, Fabio ; Ho, Khanh-Van ; Watkinson, Lisa ; Carmack, Terry L. ; Iweha, Ejike ; Li, Longbo ; Anderson, Carolyn J.</creatorcontrib><description>Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads. An analog of [177Lu]­Lu-labeled-LLP2A was previously investigated as a therapeutic agent in melanoma tumor-bearing mice, resulting in only a modest improvement in tumor growth inhibition, likely due to rapid clearance of the agent from the tumor. To improve the pharmacokinetic profile, DOTAGA-PEG4-LLP2A with a 4-(p-iodophenyl)­butyric acid (pIBA) albumin binding moiety was synthesized. We demonstrate the feasibility of this albumin binding strategy by comparing in vitro cell binding assays and in vivo biodistribution performance of [177Lu]­Lu-DOTAGA-PEG4-LLP2A ([177Lu]­Lu-1) to the albumin binding [177Lu]­Lu-DOTAGA-pIBA-PEG4-LLP2A ([177Lu]­Lu-2). In vitro cell binding assay results for [177Lu]­Lu-1 and [177Lu]­Lu-2 showed K d values of 0.40 ± 0.07 and 1.75 ± 0.40 nM, with similar B max values of 200 ± 6 and 315 ± 15 fmol/mg, respectively. In vivo biodistribution data for both tracers exhibited specific uptake in the tumor, spleen, thymus, and bone due to endogenous expression of VLA-4. Compound [177Lu]­Lu-2 exhibited a much longer blood circulation time compared to [177Lu]­Lu-1. The tumor uptake for [177Lu]­Lu-1 was highest at 1 h (∼15%ID/g) and that for [177Lu]­Lu-2 was highest at 4 h (∼23%ID/g). Significant clearance of [177Lu]­Lu-1 from the tumor occurs at 24 h (&lt;5%ID/g) while­[177Lu]­Lu-2 is retained for greater than 96 h (∼10%ID/g). An efficacy study showed that melanoma tumor-bearing mice receiving compound [177Lu]­Lu-2 given in two fractions (2 × 14.8 MBq, 14 days apart) had a greater median survival time than mice administered a single 29.6 MBq dose of compound [177Lu]­Lu-1, while a single 29.6 MBq dose of [177Lu]­Lu-2 imparted hematopoietic toxicity. The in vitro and in vivo data show addition of pIBA to [177Lu]­Lu-DOTAGA-PEG4-LLP2A slows blood clearance for a higher tumor uptake, and there is potential of [177Lu]­Lu-2 as a theranostic in fractionated administered doses.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.4c00095</identifier><identifier>PMID: 38680059</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>Molecular pharmaceutics, 2024-04, Vol.21 (6), p.2960-2969</ispartof><rights>2024 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a307t-336090a7bfdb3466f558fc7350991caba1fda8d9c9801ae7d2dfce0c8cffc2393</cites><orcidid>0000-0002-5663-282X ; 0000-0002-5656-2833</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38680059$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pun, Michael D.</creatorcontrib><creatorcontrib>Gallazzi, Fabio</creatorcontrib><creatorcontrib>Ho, Khanh-Van</creatorcontrib><creatorcontrib>Watkinson, Lisa</creatorcontrib><creatorcontrib>Carmack, Terry L.</creatorcontrib><creatorcontrib>Iweha, Ejike</creatorcontrib><creatorcontrib>Li, Longbo</creatorcontrib><creatorcontrib>Anderson, Carolyn J.</creatorcontrib><title>Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads. An analog of [177Lu]­Lu-labeled-LLP2A was previously investigated as a therapeutic agent in melanoma tumor-bearing mice, resulting in only a modest improvement in tumor growth inhibition, likely due to rapid clearance of the agent from the tumor. To improve the pharmacokinetic profile, DOTAGA-PEG4-LLP2A with a 4-(p-iodophenyl)­butyric acid (pIBA) albumin binding moiety was synthesized. We demonstrate the feasibility of this albumin binding strategy by comparing in vitro cell binding assays and in vivo biodistribution performance of [177Lu]­Lu-DOTAGA-PEG4-LLP2A ([177Lu]­Lu-1) to the albumin binding [177Lu]­Lu-DOTAGA-pIBA-PEG4-LLP2A ([177Lu]­Lu-2). In vitro cell binding assay results for [177Lu]­Lu-1 and [177Lu]­Lu-2 showed K d values of 0.40 ± 0.07 and 1.75 ± 0.40 nM, with similar B max values of 200 ± 6 and 315 ± 15 fmol/mg, respectively. In vivo biodistribution data for both tracers exhibited specific uptake in the tumor, spleen, thymus, and bone due to endogenous expression of VLA-4. Compound [177Lu]­Lu-2 exhibited a much longer blood circulation time compared to [177Lu]­Lu-1. The tumor uptake for [177Lu]­Lu-1 was highest at 1 h (∼15%ID/g) and that for [177Lu]­Lu-2 was highest at 4 h (∼23%ID/g). Significant clearance of [177Lu]­Lu-1 from the tumor occurs at 24 h (&lt;5%ID/g) while­[177Lu]­Lu-2 is retained for greater than 96 h (∼10%ID/g). An efficacy study showed that melanoma tumor-bearing mice receiving compound [177Lu]­Lu-2 given in two fractions (2 × 14.8 MBq, 14 days apart) had a greater median survival time than mice administered a single 29.6 MBq dose of compound [177Lu]­Lu-1, while a single 29.6 MBq dose of [177Lu]­Lu-2 imparted hematopoietic toxicity. The in vitro and in vivo data show addition of pIBA to [177Lu]­Lu-DOTAGA-PEG4-LLP2A slows blood clearance for a higher tumor uptake, and there is potential of [177Lu]­Lu-2 as a theranostic in fractionated administered doses.</description><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkM1OwzAQhC0EoqXwCijcuKSsYyexj6X8SkEgUc6R49jUVZwUO67E25OqpRI3TrsrzczufghdYZhiSPCNkH5qu2a9FM4KqUI_pRIAeHqExjilJGaEJ8eHntEROvN-BZDQNCGnaERYxgBSPkbvs6YK1rTxrWlr035GRehVb4KNcZ7HhahUo-qoKN6SWXSnnNmI3myUj4SPFkvlRNv53kgf6c5FL6oZZivO0YkWjVcX-zpBHw_3i_lTXLw-Ps9nRSwI5H1MSAYcRF7puiI0y3SaMi1zkgLnWIpKYF0LVnPJGWCh8jqptVQgmdRaJoSTCbre5a5d9xWU70trvFTNcIXqgi8JUEZ5hhM6SPlOKl3nvVO6XDtjhfsuMZRbpuXAtPzDtNwzHbyX-zWhsqo-OH8hDoJ0J9hmrLrg2uHrfwT_AOI8iw4</recordid><startdate>20240429</startdate><enddate>20240429</enddate><creator>Pun, Michael D.</creator><creator>Gallazzi, Fabio</creator><creator>Ho, Khanh-Van</creator><creator>Watkinson, Lisa</creator><creator>Carmack, Terry L.</creator><creator>Iweha, Ejike</creator><creator>Li, Longbo</creator><creator>Anderson, Carolyn J.</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5663-282X</orcidid><orcidid>https://orcid.org/0000-0002-5656-2833</orcidid></search><sort><creationdate>20240429</creationdate><title>Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma</title><author>Pun, Michael D. ; Gallazzi, Fabio ; Ho, Khanh-Van ; Watkinson, Lisa ; Carmack, Terry L. ; Iweha, Ejike ; Li, Longbo ; Anderson, Carolyn J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a307t-336090a7bfdb3466f558fc7350991caba1fda8d9c9801ae7d2dfce0c8cffc2393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pun, Michael D.</creatorcontrib><creatorcontrib>Gallazzi, Fabio</creatorcontrib><creatorcontrib>Ho, Khanh-Van</creatorcontrib><creatorcontrib>Watkinson, Lisa</creatorcontrib><creatorcontrib>Carmack, Terry L.</creatorcontrib><creatorcontrib>Iweha, Ejike</creatorcontrib><creatorcontrib>Li, Longbo</creatorcontrib><creatorcontrib>Anderson, Carolyn J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pun, Michael D.</au><au>Gallazzi, Fabio</au><au>Ho, Khanh-Van</au><au>Watkinson, Lisa</au><au>Carmack, Terry L.</au><au>Iweha, Ejike</au><au>Li, Longbo</au><au>Anderson, Carolyn J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2024-04-29</date><risdate>2024</risdate><volume>21</volume><issue>6</issue><spage>2960</spage><epage>2969</epage><pages>2960-2969</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads. An analog of [177Lu]­Lu-labeled-LLP2A was previously investigated as a therapeutic agent in melanoma tumor-bearing mice, resulting in only a modest improvement in tumor growth inhibition, likely due to rapid clearance of the agent from the tumor. To improve the pharmacokinetic profile, DOTAGA-PEG4-LLP2A with a 4-(p-iodophenyl)­butyric acid (pIBA) albumin binding moiety was synthesized. We demonstrate the feasibility of this albumin binding strategy by comparing in vitro cell binding assays and in vivo biodistribution performance of [177Lu]­Lu-DOTAGA-PEG4-LLP2A ([177Lu]­Lu-1) to the albumin binding [177Lu]­Lu-DOTAGA-pIBA-PEG4-LLP2A ([177Lu]­Lu-2). In vitro cell binding assay results for [177Lu]­Lu-1 and [177Lu]­Lu-2 showed K d values of 0.40 ± 0.07 and 1.75 ± 0.40 nM, with similar B max values of 200 ± 6 and 315 ± 15 fmol/mg, respectively. In vivo biodistribution data for both tracers exhibited specific uptake in the tumor, spleen, thymus, and bone due to endogenous expression of VLA-4. Compound [177Lu]­Lu-2 exhibited a much longer blood circulation time compared to [177Lu]­Lu-1. The tumor uptake for [177Lu]­Lu-1 was highest at 1 h (∼15%ID/g) and that for [177Lu]­Lu-2 was highest at 4 h (∼23%ID/g). Significant clearance of [177Lu]­Lu-1 from the tumor occurs at 24 h (&lt;5%ID/g) while­[177Lu]­Lu-2 is retained for greater than 96 h (∼10%ID/g). An efficacy study showed that melanoma tumor-bearing mice receiving compound [177Lu]­Lu-2 given in two fractions (2 × 14.8 MBq, 14 days apart) had a greater median survival time than mice administered a single 29.6 MBq dose of compound [177Lu]­Lu-1, while a single 29.6 MBq dose of [177Lu]­Lu-2 imparted hematopoietic toxicity. The in vitro and in vivo data show addition of pIBA to [177Lu]­Lu-DOTAGA-PEG4-LLP2A slows blood clearance for a higher tumor uptake, and there is potential of [177Lu]­Lu-2 as a theranostic in fractionated administered doses.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>38680059</pmid><doi>10.1021/acs.molpharmaceut.4c00095</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5663-282X</orcidid><orcidid>https://orcid.org/0000-0002-5656-2833</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1543-8384
ispartof Molecular pharmaceutics, 2024-04, Vol.21 (6), p.2960-2969
issn 1543-8384
1543-8392
language eng
recordid cdi_proquest_miscellaneous_3048496124
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
title Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A25%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Albumin-Binding%20Lutetium-177-Labeled%20LLP2A%20Derivatives%20as%20Theranostics%20for%20Melanoma&rft.jtitle=Molecular%20pharmaceutics&rft.au=Pun,%20Michael%20D.&rft.date=2024-04-29&rft.volume=21&rft.issue=6&rft.spage=2960&rft.epage=2969&rft.pages=2960-2969&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.4c00095&rft_dat=%3Cproquest_cross%3E3048496124%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a307t-336090a7bfdb3466f558fc7350991caba1fda8d9c9801ae7d2dfce0c8cffc2393%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3048496124&rft_id=info:pmid/38680059&rfr_iscdi=true